ID: ALA62811

Max Phase: Preclinical

Molecular Formula: C14H12N2O

Molecular Weight: 224.26

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C1CCc2cc(-c3cccnc3)ccc2N1

Standard InChI:  InChI=1S/C14H12N2O/c17-14-6-4-11-8-10(3-5-13(11)16-14)12-2-1-7-15-9-12/h1-3,5,7-9H,4,6H2,(H,16,17)

Standard InChI Key:  MPGBYGNPFRLHAO-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 224.26

Molecular Weight (Monoisotopic): 224.0950

AlogP: 2.63

#Rotatable Bonds: 1

Polar Surface Area: 41.99

Molecular Species: NEUTRAL

HBA: 2

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 3

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.77

CX Basic pKa: 4.73

CX LogP: 1.95

CX LogD: 1.95

Aromatic Rings: 2

Heavy Atoms: 17

QED Weighted: 0.81

Np Likeness Score: -0.99

References

1. Alabaster CT, Bell AS, Campbell SF, Ellis P, Henderson CG, Roberts DA, Ruddock KS, Samuels GM, Stefaniak MH..  (1988)  2(1H)-quinolinones with cardiac stimulant activity. 1. Synthesis and biological activities of (six-membered heteroaryl)-substituted derivatives.,  31  (10): [PMID:2845085] [10.1021/jm00118a034]

2. Leclerc G, Marciniak G, Decker N, Schwartz J..  (1986)  Cardiotonic agents. 2. Synthesis and structure-activity relationships in a new class of 6-, 7-, and 8-pyridyl-2(1H)-quinolone derivatives.,  29  (12): [PMID:3783604] [10.1021/jm00162a003]

3. Martinez GR, Walker KA, Hirschfeld DR, Bruno JJ, Yang DS, Maloney PJ..  (1992)  3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.,  35  (4): [PMID:1311763] [10.1021/jm00082a002]

4. Lucas S, Heim R, Ries C, Schewe KE, Birk B, Hartmann RW..  (2008)  In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.,  51  (24): [PMID:19049427] [10.1021/jm800888q]

5. Lucas S, Negri M, Heim R, Zimmer C, Hartmann RW..  (2011)  Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.,  54  (7): [PMID:21384875] [10.1021/jm101470k]

6. Hu Q, Yin L, Hartmann RW..  (2012)  Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer.,  55  (16): [PMID:22861193] [10.1021/jm3004637]

7. Grombein CM, Hu Q, Rau S, Zimmer C, Hartmann RW..  (2015)  Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase.,  90  [PMID:25528333] [10.1016/j.ejmech.2014.12.022]

Source

Source(1):

• Scientific Literature